A Study of Medical Expenses for Infectious Diseases in a Ventilator-associated Event

Abstract

In 2013, The Centers for Disease Control and Prevention (CDC) revised the definition of Ventilator-Associated Pneumonia (VAP) surveillance, and VAP in Ventilator-Associated Events (VAE). Although VAE affects not only the treatment period and prognosis, but also the medical economy, there is no report on the effect of VAE occurrence on the Japanese medical economy. For the VAE, we calculated the cost (procedure, drug fee, material cost), from hospitalization to discharge, from patients with infection-related Ventilator-Associated Complication (IVAC), and compared them in terms of age and sex. We examined the additional medical expenses of the onset group by matching VAE patients with disease-free patients on a one-to-one basis. In the IVAC onset group, the additional medical cost was 2.38 million yen on average, but there was no statistically significant difference compared to the non-onset group.